Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $165.6 million.

  • Editas Medicine's Cash & Equivalents rose 7285.25% to $165.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.6 million, marking a year-over-year increase of 7285.25%. This contributed to the annual value of $131.5 million for FY2024, which is 638.0% up from last year.
  • Editas Medicine's Cash & Equivalents amounted to $165.6 million in Q3 2025, which was up 7285.25% from $138.5 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Cash & Equivalents ranged from a high of $354.9 million in Q1 2021 and a low of $64.4 million during Q2 2024
  • In the last 5 years, Editas Medicine's Cash & Equivalents had a median value of $141.5 million in 2022 and averaged $171.0 million.
  • Per our database at Business Quant, Editas Medicine's Cash & Equivalents crashed by 7081.7% in 2024 and then soared by 11499.05% in 2025.
  • Over the past 5 years, Editas Medicine's Cash & Equivalents (Quarter) stood at $203.5 million in 2021, then plummeted by 30.46% to $141.5 million in 2022, then fell by 12.63% to $123.7 million in 2023, then rose by 6.38% to $131.5 million in 2024, then increased by 25.93% to $165.6 million in 2025.
  • Its last three reported values are $165.6 million in Q3 2025, $138.5 million for Q2 2025, and $138.7 million during Q1 2025.